Introduction
============

Advances in genomics are providing new insights into the biology of psychiatric disorders.^[@bib1]^ At the same time, advances in magnetic resonance imaging (MRI) are transforming our understanding of the structural and functional organization of the human brain.^[@bib2]^ Classic twin studies, as well as genome-wide association studies (GWAS), show that the structure of the human brain is strongly shaped by genetics.^[@bib3],\ [@bib4]^ Altered brain structure has been reported in individuals with psychiatric disorders^[@bib5]^ and in asymptomatic individuals with a family history,^[@bib6]^ suggesting that genetic influences on disease risk are partly mediated by changes in neuroanatomy. It is thus somewhat surprising that large-scale imaging genetics studies have thus far shown little overlap between genome-wide significant loci associated with brain structure and those associated with psychiatric disorders.^[@bib4],\ [@bib7],\ [@bib8]^ One potential explanation for this discrepancy is that most imaging-genetic studies use data collected in adolescence or adulthood. As such they cannot address the reality that many psychiatric disorders are unfolding processes with roots in prenatal and early postnatal development.^[@bib9],\ [@bib10]^

The prenatal--early postnatal period represents the foundational phase of human brain development and relies on precise spatiotemporal regulation of gene expression.^[@bib11]^ Many genes associated with mental illness show elevated expression in early life,^[@bib10],\ [@bib12]^ and early aberrations in neurodevelopment relevant to psychiatric disorders can be captured via MRI as evidenced by studies of infants at high familial risk for schizophrenia or autism spectrum disorders (ASD).^[@bib13],\ [@bib14]^ In addition, twin studies indicate infant brain volumes are highly heritable.^[@bib15]^ Consequently, imaging-genetic studies in infants could provide new insights into the origins of psychiatric disorders. Furthermore, the infant brain is highly plastic and a promising target for therapeutic interventions. To investigate how genetic variation impacts prenatal and early postnatal brain development, we conducted a GWAS of global brain tissue volumes in a unique cohort of infants who received high-resolution MRI scans of the brain around 5 weeks of age.

Materials and methods
=====================

Subjects
--------

A total of 561 infants (300 male, 261 female) between 0 and 24 weeks of age, encompassing 295 singletons or unpaired twins, 17 sibling pairs and 232 twins (61 same-sex dizygotic (DZ) pairs, 37 same-sex monozygotic (MZ) pairs and 18 opposite-sex DZ pairs). Overall, 63% of subjects are European ancestry; remaining subjects are primarily African ancestry. See [Supplementary Methods](#sup1){ref-type="supplementary-material"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"} for additional information.

Image acquisition and analysis
------------------------------

T1- and T2-weighted scans were acquired with either a Siemens Allegra head-only 3 T scanner (*N*=512) or a Siemens TIM Trio 3T scanner (*N*=49) (Siemens Medical Supplies, Erlangen, Germany). See [Supplementary Methods](#sup1){ref-type="supplementary-material"} for acquisition parameters. ANOVA performed in 561 unrelated subjects indicated platform (Allegra or Trio) had a significant impact on gray matter volume and a marginal effect on intracranial volume (ICV). Acquisition parameters within each platform did not significantly affect brain volumes. Platform was included as a covariate in all analyses. Automatic segmentation of brain tissue into gray matter (GM), white matter (WM) and cerebrospinal fluid (CSF) was performed using an atlas-based expectation-maximization segmentation algorithm using T1- and T2-weighted images as in ref. [@bib16]. ICV represents the sum of GM, WM, and CSF.

Genome-wide genotyping
----------------------

Genotyping of single-nucleotide polymorphisms (SNPs) was carried out using Affymetrix Axiom Genome-Wide LAT and Exome arrays. Samples were randomized across 96-well plates. Each plate contained a common control sample. Population stratification was assessed using principle component analysis (PCA).^[@bib17]^ See [Supplementary Methods](#sup1){ref-type="supplementary-material"} for additional details. Imputation was performed with MACH-Admix^[@bib18]^ using the 1000 Genomes Project (1000G) reference panel (phase1_release_v3.20101123).^[@bib19],\ [@bib20]^ To evaluate the quality of imputed SNPs, we computed mean *R*^2^ for varying minor allele frequency (MAF) categories and *R*^2^ cutoffs ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).^[@bib21]^ We retained SNPs with average *R*^2^\>0.8 and excluded SNPs with MAF \<0.01.

Statistical methods
-------------------

We investigated associations between 8 762 422 SNPs and four infant brain volume measures (ICV, GM, WM and CSF). The first three genotypic principal components were included as covariates as was scanner type. ICV was a covariate for GM, WM and CSF. Additional covariates were selected via adaptive lasso from a comprehensive set of demographic and medical history variables ([Supplementary Methods](#sup1){ref-type="supplementary-material"}). For ICV and WM, we included birth weight, gestational age at birth, sex and age at MRI. For GM, we included birth weight, gestational age at birth and age at MRI. For CSF, we included age at MRI.

To account for subject correlation among MZ and DZ twins, we applied ACE-based linear mixed effects models.^[@bib21]^ The ACE model not only distinguishes correlation among MZ and DZ twins, it also includes common environmental effect as well as random effect in the linear mixed effect model with restricted maximum likelihood (REML) for optimization. Association analysis was performed with two-sided likelihood ratio tests. *P*-values \<1.25 × 10^−8^ were considered genome-wide significant (Bonferroni correction for four MRI phenotypes, which is from the conventional GWAS threshold of 5 × 10^−8^\[ref. [@bib22]\] divided by four). The suggestive significance level for this correction was *P*=1.25 × 10^−6^, which is derived from the conventional suggestive GWAS threshold of 5 × 10^−6^\[ref. [@bib23]\] divided by four. The phenotypic variance explained by each SNP was calculated as *h*^2^=*β*\'^2^var(*X*)/(*β*′^2^var(*X*)+σ~*a*~^2^+ σ~*c*~^2^+σ~*e*~^2^), where *β*′ is the adjusted effect size of the SNP through an approximate conditional-likelihood approach to correct for the overestimation of effect size caused by winner\'s curse,^[@bib24]^ var(*X*) is the variance of SNP genotype, and σ~*a*~^2^, σ~*c*~^2^ and σ~*e*~^2^are the variance explained by shared genetic effect, shared environment effect and random effect, respectively. We simulated statistical power under a series of major genetic effect *β* values with varying minor allele frequencies. We set the variance explained by genetic effect to 0.2 and the random error variation σ~*e*~^2^ to 1. Sample size is sufficient to discover a genetic effect on the order of \~8% with 80% power ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

We ran multiple sensitivity analyses to evaluate the robustness of our findings. We examined top SNPs in individuals with European ancestry (based on PCA, *N*=356), individuals with non-European (primarily African) ancestry (based on PCA, *N*=205), individuals born after 32 weeks gestation (*N*=530), a subsample excluding offspring of mothers with a confirmed diagnosis of schizophrenia or bipolar disorder (*N*=526), a subsample excluding children who spent more than 24 hours in neonatal intensive care (*N*=427), a subsample consisting only of unrelated individuals (*N*=423), and a subsample including only the two most common image acquisition sequences (*N*=538). We also ran a sensitivity analysis using the full sample, but a reduced set of covariates. As some of our phenotypes were moderately correlated ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}), we also applied a PCA analysis to the brain volumes and used the top three PCs as GWAS phenotypes. Finally, to ensure the validity of our most significant GWAS findings, we performed permutation tests for the two most significant SNPs ([Supplementary Methods](#sup1){ref-type="supplementary-material"}).

We calculated fixation index (F~ST~) for all linkage disequilibrium (LD)-independent SNPs with *P*-values \<1.25 × 10^−6^ to further evaluate potential confounding by population stratification. We checked major and minor allele frequencies within our sample using maternal-reported and genetic ancestry (from PCA), and cross-checked our data with allele frequencies provided through the 1000 Genomes Project (1000G) (phase I, version 3).^[@bib25]^

After performing LD-pruning (---indep-pairwise 50 5 0.5: 50 bp moving window at step of 5 bp with *r*^2^ threshold of 0.5 in PLINK, see [Supplementary Methods](#sup1){ref-type="supplementary-material"}), we tested for enrichment of prenatally expressed genes as described in ref. [@bib26] using increasingly liberal *P*-value thresholds. This approach down-weights noisy signal from null SNPs that are invariably incorporated, especially at large *P*-value thresholds, while capturing true, subtle signals that increase power for association.^[@bib27],\ [@bib28]^ Each SNP was assigned to the nearest gene within 2 megabases. Elevated prenatal expression was defined as a fetal/postnatal log2 fold-change of 0.5 or greater. Analyses were performed using both the microarray-based 'BrainCloud' dorsolateral prefrontal cortex transcriptome^[@bib29]^ and the RNA sequencing-based Brainspan transcriptome of 15 brain regions.^[@bib30]^

Using two-sided exact binomial tests (sign test) after LD-pruning, we compared our data to two large-scale neuroimaging GWAS conducted in older individuals: ENIGMA2,^[@bib31]^ a primarily adult sample, and the Philadelphia Neurodevelopmental Cohort (PNC),^[@bib32]^ a primarily adolescent sample (See [Supplementary Methods](#sup1){ref-type="supplementary-material"} for details). We used the---score function in PLINK and LD-pruned genotype data from our neonate cohort to generate polygenic scores for ICV, GM and WM at nine different *P*-value thresholds (ambiguous SNPs were not included). These 'neonatal scores' were used to predict the equivalent phenotype in the PNC cohort (covarying for age, sex and first three ancestry PCs). In a similar manner, we generated polygenic scores for ICV, GM and WM using the PNC cohort and used these 'adolescent scores' to predict the equivalent phenotype in neonates. Covariates were the same as in univariate neonate analyses. Finally, we generated polygenic scores for ICV using ENIGMA2 data. Note that data on GM and WM is not available for ENIGMA2. This 'adult ICV score' was used to predict ICV in the neonate cohort and PNC cohorts. Only summary-level GWAS data was available for ENIGMA2; consequently adult ICV never served as a dependent variable. The same procedure was used to generate genetic predisposition scores for schizophrenia^[@bib33]^ and ASD.^[@bib34]^ Resulting risk scores were used as predictors for neonatal brain volumes.

Gene set-enrichment analysis (GSEA) was performed on each brain volume GWAS with MAGMA.^[@bib35]^ We tested candidate pathways implicated in psychiatric disorders including glutamatergic postsynaptic proteins comprising activity-regulated cytoskeleton-associated protein (ARC)^[@bib36],\ [@bib37],\ [@bib38]^ and *N*-methyl-[d]{.smallcaps}-aspartate receptor (NMDAR) complexes,^[@bib38],\ [@bib39]^ genes whose mRNAs bind to fragile X mental retardation protein (FMRP),^[@bib36],\ [@bib37],\ [@bib39],\ [@bib40],\ [@bib41]^ calcium channels^[@bib34],\ [@bib40],\ [@bib42]^ and genes involved in histone methylation.^[@bib43]^ We focused on pathways supported by convergent evidence from genome-wide screens for common and exonic variation and CNVs. Given our univariate results, we also tested genes with *REST* binding sites^[@bib44]^ and Rbfox targets. For the latter analysis, we used genes with RBFOX2 count \>4 or summed RBFOX1 and RBFOX3 \>12.^[@bib45]^

PennCNV and Partek Genomics Suite 6.6 were used for CNV calling from signal intensity files of the Affymetrix Axiom Genotype array.^[@bib46]^ Included CNVs had SNP coverage \>15, length \>100 kb, and for PennCNV, confidence score ⩾10. We excluded CNVs with \>50% overlap with common CNVs (freq \>1% in EUR population^[@bib47]^ or our population) or regions of known rearrangement (chr14:105573485--107197774 and chr22:22473003--23188329). CNVs occuring in both PennCNV and Partek were considered validated CNVs. See [Supplementary Appendix 1](#sup1){ref-type="supplementary-material"} for details. Linear mixed effects models were used to test whether CNV burden (number of CNV-affected genes per subject) predicted ICV, GM, WM and CSF. Covariates were the same as in univariate analyses. Finally, we determined whether any one in the sample carried a rare CNV that overlapped with known neuropsychiatric CNVs ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}).

Experiments were undertaken with the understanding and written consent of each subject's mother or father, with the approval of the Institutional Review Board of the University of North Carolina (UNC) School of Medicine.

Code availability
-----------------

Computer code used to generate study results can be found at <http://www.bios.unc.edu/research/genomic_software/CorrMeta/ace/>.

Results
=======

[Table 1](#tbl1){ref-type="table"} displays all LD-independent SNPs with *P*-values \<1.25 × 10^−6^. Quantile--quantile plots are displayed in [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}. Locus zoom plots are displayed in [Supplementary Figures 3--6](#sup1){ref-type="supplementary-material"}. Lambda is 1.01 for ICV and WM, 1.00 for GM and 0.98 for CSF. Lambda-1000 is 1.01 for ICV, WM and GM, and 0.96 for CSF. An intronic SNP in *IGFBP7* (rs114518130) achieved genome-wide significance for GM (*P*=4.15 × 10^−10^, [Figure 1](#fig1){ref-type="fig"} and [Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). An intronic SNP in *WWOX* (rs10514437) fell just short of genome-wide significance for WM (*P*=1.56 × 10^−8^, [Figure 1](#fig1){ref-type="fig"} and [Supplementary Figures 4 and 7](#sup1){ref-type="supplementary-material"}). Additional loci nearing genome-wide significance were located near (within 500 kb) transcriptional regulators expressed in developing brain, psychiatric GWAS associations, and genes involved in neurotransmitter signaling and neural development ([Supplementary Table 5](#sup1){ref-type="supplementary-material"}). LD-independent SNPs with *P*-values \<1.25 × 10^−6^ were associated with absolute percent differences of 0.85--9.54% in volume per risk allele, explaining 0.27--6.52% of the phenotypic variance (after correction for 'winner's curse'). Effect sizes in primary analyses were highly similar to effect sizes in sensitivity analyses ([Supplementary Table 6](#sup1){ref-type="supplementary-material"}) with the exception of rs113668862 (association with CSF, *P*=5.9 × 10^−7^), which showed no effect on CSF in non-European populations. Similar genes emerged when using the top three PCs from a PCA analysis of the brain volumes as GWAS phenotypes ([Supplementary Table 7](#sup1){ref-type="supplementary-material"}).

Permutation testing yielded an empirical *P*-value of 8 × 10^−8^ for rs10514437's association with WM and an empirical *P*-value of 1 × 10^−8^ for rs114518130's association with GM. Low empirical *P*-values suggest these findings are reliable and robust.

F~ST~ values \>0.05, indicating potential confounding by ancestry, were observed for rs9831671 (association with ICV, *P*=9.49 × 10^−7^), rs7786147 (association with GM, *P*=1.15 × 10^−7^), rs2565117 (association with GM, *P*=2.88 × 10^−7^) and rs113668862 (association with CSF, *P*=5.9 × 10^−7^). Although F~ST~ values were below 0.05 for our top hits in *IGFBP7* and *WWOX*, we note that the minor (A) allele for the *IGFBP7* SNP is very rare in populations of European ancestry ([Supplementary Table 8](#sup1){ref-type="supplementary-material"}). We were unable to run sensitivity analysis in individuals of European ancestry as the minor allele did not occur in this group.

Three genes, *TOX3, FRG1* and *c7orf11* (*MPLKIP*) show elevated prenatal expression across multiple brain regions ([Supplementary Appendix 2](#sup1){ref-type="supplementary-material"}; [Supplementary Table 9](#sup1){ref-type="supplementary-material"}). *KLF13, WWOX, SLC13A3, HTR1B, MYOM1, ZMAT4, CNDP1, CACNB2* and *SEC14L5* show a strong increase in expression from prenatal to postnatal life. *EYA2, USP44, OPA1, SLC35F4, CTH, RBFOX1* and *METTL4* show elevated prenatal expression in a small subset of brain regions. Examination of exon level expression data from Brainspan suggests *METTL4*, *C16orf62* and *RBFOX1* have specific isoforms with differentially regulated expression across the lifespan ([Supplementary Appendix 3](#sup1){ref-type="supplementary-material"}). Tests for enrichment of prenatally expressed genes were significant at multiple thresholds across multiple brain regions ([Figure 2](#fig2){ref-type="fig"}).

Comparing our neonate cohort to the adolescent cohort, sign tests for WM were significant at thresholds of *P*\<0.001, *P*\<0.01 and *P*\<0.1 ([Figure 3](#fig3){ref-type="fig"}). Percent overlap is small with 53.8, 51.2 and 50.6% of SNPs showing the same direction of effect versus 50% expected by chance. Comparing our neonate cohort to the adult cohort, the sign test for ICV is significant at the threshold of *P*\<0.1 with 50.40% overlap. Comparing the adolescent cohort to the adult cohort, the sign test for ICV is significant at the threshold of *P*\<0.1 with 50.80% overlap.

Neonatal polygenic scores for WM showed positive associations with adolescent WM at thresholds between *P*\<0.01 and *P*\<0.5 ([Figure 4](#fig4){ref-type="fig"}). Adolescent WM scores showed positive associations with neonatal WM at 7 of 9 *P*-value thresholds, and adolescent GM scores showed a positive association with neonatal GM at the threshold of *P*\<0.1. Adult polygenic scores for ICV did not predict neonatal ICV, but did predict adolescent ICV at 8 of 9 *P*-value thresholds. When comparing across ages, polygenic scores explained between 0.4 and 1.6% of variance after adjusting for covariates. Scatterplots of significant relationships can be found in [Supplementary Figure 8](#sup1){ref-type="supplementary-material"}. To put these numbers in context, neonatal polygenic scores explain between 74 and 93% of variance in neonatal brain volumes after adjusting for covariates and adolescent polygenic scores explain between 67 and 93% of variance in adolescent brain volumes after adjusting for covariates.

[Supplementary Table 10](#sup1){ref-type="supplementary-material"} lists all LD-independent SNPs with *P*-values \<1.25 × 10^−6^ in the neonate and compares them to equivalent SNPs and phenotypes in PNC and ENIGMA2. The SNP tagging *EYA2* is nominally significant in ENIGMA2 (*P*=0.048) with the same direction of effect. No other overlapping SNPs are significant in PNC or ENIGMA2, but some of our top hits are not represented in PNC data as they failed imputation quality control. Previously published genome-wide significant hits for ICV^[@bib8],\ [@bib48],\ [@bib49]^ in adults did not predict ICV in infants ([Supplementary Table 11](#sup1){ref-type="supplementary-material"}), although we were unable to examine rs9303535 as it was not in the 1000G reference database and hence not imputed. No suitable proxy SNPs were available.

Genetic predisposition scores for schizophrenia and ASD did not predict neonatal brain volumes ([Supplementary Figure 9](#sup1){ref-type="supplementary-material"}). Regarding GSEA, Rbfox targets showed a nominally significant association with CSF, but no gene sets achieved significance after correction for multiple comparisons ([Supplementary Table 12](#sup1){ref-type="supplementary-material"}).

CNV burden was not significantly associated with any of the neuroimaging traits examined ([Supplementary Figure 10](#sup1){ref-type="supplementary-material"}). Four individuals carried a rare CNV, which overlapped with a known neuropsychiatric CNV. Percent overlap ranged from 0.27 to 96.29%. All CNVs affected at least one gene also present in the known neuropsychiatric CNV. Two of these children had a history of psychiatric illness in one or both parents (attention deficit disorder or anxiety disorder). Review of medical records indicated that one child had delayed speech and fine motor skills at 2 years of age. Long-term follow-up data was not available. Examination of individual value plots suggested these individuals had brain volumes in the normal range at this age ([Supplementary Figure 11](#sup1){ref-type="supplementary-material"}).

Discussion
==========

The prenatal and early postnatal period represents a critical window in brain development with long-term implications for cognition^[@bib50],\ [@bib51]^ and psychiatric risk.^[@bib9],\ [@bib10]^ In this first GWAS of infant neuroimaging phenotypes, an intronic SNP in *IGFBP7* (rs114518130) achieved genome-wide significance for GM. An intronic SNP in *WWOX* (rs10514437) fell just short of genome-wide significance for WM. Although *IGFBP7* has been implicated in learning and memory,^[@bib52]^ it is perhaps even more intriguing that this SNP is within 100 kb of *REST*, which encodes a master negative regulator of neurogenesis.^[@bib44]^ Experimental manipulation of the *REST/NRSF-SWI/SNF* chromatin remodeling complex alters expression of several GWAS-supported schizophrenia genes.^[@bib53]^ However, GSEA analysis of *REST* targets did not reach significance, somewhat diminishing the case that *REST* is the causal element in this association. Mutations in *WWOX* are associated with brain phenotypes including autosomal recessive spinocerebellar ataxia-12 (SCAR12; MIM \#614322), epilepsy, mental retardation and microcephaly. MRI studies are limited, but hypomyelination, hypoplasia of the corpus callosum and posterior white matter hyperintensities have been reported. In adult human brains, levels of the protein encoded by *WWOX* (WOX1) are high in neuronal axons and nerve bundles such as corpus callosum and striatal fascicles,^[@bib54]^ consistent with our observed association with WM.

Many top associations tag transcriptional regulators expressed in developing brain (*KLF13, LMCD1, TOX3* and *TBX4*), though none are known eQTLs. Other genes with strong biological plausibility include *CACNB2*, a calcium channel subunit which has emerged in schizophrenia GWAS,^[@bib33]^ *HTR1B*, which encodes the 5-hydroxytryptamine (serotonin) receptor 1B, and *RBFOX1*, an RNA splicing factor, which regulates expression of large genetic networks during early neuronal development.^[@bib55]^ Most of these genes show a strong increase in expression from the prenatal to the postnatal period, whereas *TOX3* shows elevated prenatal expression. Examination of exon level expression data suggests the first several exons of *RBFOX1* show elevated prenatal expression. When examining more permissive *P*-value thresholds, there was evidence of significant prenatal expression enrichment for all phenotypes examined.

We compared our results to two large-scale neuroimaging GWAS, one focused on adolescents (PNC)^[@bib32]^ and one on adults (ENIGMA2).^[@bib31]^ These comparisons do not represent a conventional replication sample. Instead, they represent a test of whether there are shared genetic determinants of global brain volumes at differing ages. Sign tests and polygenic score analyses suggest genetic variants influencing neonatal WM have detectable effects in adolescence. Polygenic score analyses suggest genetic variants influencing ICV in adults have detectable effects in adolescence. However, percent overlap in sign tests was minimal and the percent of variance explained by polygenic scores was small. The overall pattern of results suggests genetic determinants of global brain volumes are highly distinct at different ages. Variants associated with neonatal brain volumes are likely located in genes involved with foundational prenatal processes including neurogenesis, neuronal migration and differentiation, programmed cell death, dendritogenesis and axonogenesis.^[@bib56]^ Variants associated with adolescent brain volumes are likely located in genes involved in postnatal neurodevelopmental processes including synaptogenesis during early childhood and synaptic/dendritic pruning during early adolescence. Variants associated with adult brain volumes likely represent synaptic/dendritic pruning in late adolescence and perhaps neurodegenerative events associated with aging.^[@bib56]^

Genetic predisposition scores for schizophrenia and ASD did not predict global brain volumes in neonates. Results are similar to a recent study, which found no evidence of genetic overlap between schizophrenia risk and ICV in adults.^[@bib7]^ To our knowledge, this is the first study to apply a similar approach for ASD risk. In addition, although rare genic CNVs are increased in ASD^[@bib57]^ and schizophrenia,^[@bib58]^ CNV burden did not predict global brain volumes in neonates. Null findings should be considered in light of several qualifiers. First, genetic variants associated with disease may influence neurodevelopmental processes occurring at a resolution not captured by MRI. Second, other neuroimaging phenotypes may be more relevant to ASD and schizophrenia (for example, cortical thickness and surface area, ventricular volume, diffusion tensor imaging or functional activity/connectivity).^[@bib13],\ [@bib59],\ [@bib60],\ [@bib61],\ [@bib62],\ [@bib63]^ Third, longitudinal change in neuroimaging phenotypes may be more relevant to ASD and schizophrenia than cross-sectional measures.^[@bib64]^ Finally, although many psychiatric risk genes show elevated expression in early life^[@bib10],\ [@bib12]^ differences in global brain volumes may not arise until later in life. Regarding ASD, 6-month-old infants at high familial risk do not have larger brain volumes than low risk infants, despite reports of generalized enlargement in older children with ASD.^[@bib65]^ Regarding schizophrenia, neonates at high familial risk do have larger GM volume than controls, but this affect is restricted to males.^[@bib14]^ Future studies with larger samples should address how genetic predisposition and CNV burden influence neurodevelopmental trajectories across infancy and childhood, as well as possible interactions with sex. Larger samples would also allow stable estimates of SNP-sense heritability to be calculated.

In conclusion, we have shown that common genetic variation influences infant brain volumes. Several individual loci identified in this study have clear relevance to intellectual disability and mental illness, although genetic predisposition scores for schizophrenia and ASD did not predict variation in our sample. To our knowledge, this is the first study of its kind, consequently independent replication is critical. This is particularly true for the intronic SNP in *IGFBP7,* which has a low minor allele frequency, was imputed, and was not present in the largest racial/ethnic group in the study. Nevertheless, the current results suggest this area of research will be fruitful. Ultimately, by identifying genes contributing to developmental phenotypes, it may be possible to develop treatments that normalize adverse trajectories, preventing the onset of psychiatric disorders or reducing their severity.
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![Common genetic variants associated with infant brain volumes. Manhattan plots colored with a scheme that matches the corresponding tissue volume (middle) are shown (yellow is white matter (WM); green is gray matter (GM); blue is cerebrospinal fluid (CSF)). Genome-wide significance is shown for the threshold of *P*=1.25 × 10^−8^ (gray dotted line). The green line indicates the threshold of *P*=1.25 × 10^−6^. The most significant single-nucleotide polymorphism (SNP) for each phenotype is labeled.](tp2017159f1){#fig1}

![Enrichment of prenatally expressed genes at multiple *P*-value thresholds. After LD-pruning, each single-nucleotide polymorphism (SNP) was assigned to the nearest gene within 2 megabases. Elevated prenatal expression was defined as a fetal/postnatal log2 fold-change threshold of 0.5. Analyses were performed using both the microarray-based 'BrainCloud' dorsolateral prefrontal cortex (DLPFC) transcriptome^[@bib31]^ and the RNA sequencing-based Brainspan transcriptome of 15 different brain regions.^[@bib32]^ Left panels show −log~10~ *P-*values. Orange line represents the threshold for statistical significance. Right panels show percentage of genes with elevated prenatal expression. (**a**) intracranial volume (ICV). (**b**) white matter (WM). (**c**) gray matter (GM). (**d**) CSF.](tp2017159f2){#fig2}

![Sign tests suggest minimal overlap between common variants impacting brain volumes in neonates, adolescents and adults. (**a**) Left panel shows --log~10~ *P-*values for two-sided exact binomial tests comparing single-nucleotide polymorphisms (SNPs) impacting intracranial volume (ICV) and ICV-adjusted white matter (WM) and gray matter (GM) in neonates to the same SNPs in adolescents (PNC). Right panel shows percent overlap. Tests for ICV-adjusted WM are significant (*P*=0.02, 0.04 and 0.01) at the thresholds of *P*\<0.001, *P*\<0.01, and *P*\<0.1, respectively. (**b**) Left panel shows --log~10~*P-*values for two-sided exact binomial tests comparing SNPs impacting ICV in neonates to the same SNPs in adults (ENIGMA2). Right panel shows percent overlap. Test is significant at the threshold of *P*\<0.1 (*P*=0.02). (**c**) Left panel shows --log~10~ *P*-values for two-sided exact binomial tests comparing SNPs impacting ICV in adolescents (PNC) to the same SNPs in adults (ENIGMA2). Right panel shows percent overlap. Test is significant at the threshold of *P*\<0.1 (*P*=0.001). \* indicates significance.](tp2017159f3){#fig3}

![Polygenic scores for neonatal, adolescent and adult brain volumes suggest genetic determinants of global brain volumes are highly distinct at different ages. (**a**) Left panel shows --log~10~ *P*-values for the association between neonatal polygenic scores for intracranial volume (ICV), ICV-adjusted white matter (WM), and ICV-adjusted gray matter (GM) and the matching phenotype in adolescents (PNC). Middle panel shows the effect size and direction of effect (Beta). Right panel shows the *r*^2^ value (percentage of variance explained after adjusting for covariates). (**b**) Left panel shows --log~10~ *P*-values for the association between adolescent polygenic scores for ICV, ICV-adjusted WM, and ICV-adjusted GM and the matching phenotype in this neonatal cohort. Middle panel shows the effect size and direction of effect (Beta). Right panel shows the *r*^2^ value (percentage of variance explained after adjusting for covariates). (**c**) Left panel shows --log~10~ *P*-values for the association between adult (ENIGMA2) polygenic scores for ICV and ICV in this neonatal cohort. Middle panel shows the effect size and direction of effect (Beta). Right panel shows the *r*^2^ value (percentage of variance explained after adjusting for covariates). (**d**) Left panel shows --log~10~ *P*-values for the association between adult (ENIGMA2) polygenic scores for ICV and ICV in adolescents (PNC). Middle panel shows the effect size and direction of effect (Beta). Right panel shows the *r*^2^ value (percentage of variance explained after adjusting for covariates).\* indicates significance.](tp2017159f4){#fig4}

###### LD-independent SNPs with *P*-values smaller than 1.25 × 10^−6^

  *Tissue volume*   *Chr*                  *Best SNP*                 *A1*   *A2*  *MAF*   *Effect size*   *Likelihood ratio*   *P-value*   *Variance explained*   *Diff./allele*     *Closest protein coding gene (±500 kb)*
  ----------------- ------- ---------------------------------------- ------ ------ ------- --------------- -------------------- ----------- ---------------------- ---------------- --------------------------------------------
  ICV               15                     rs8030297                   T      G    0.07    −32 231         28.46                9.56E−08    2.47                   −6.73                              *KLF13*
                    20                     rs4809613                   A      G    0.17    −19 053         24.38                7.91E−07    0.36                   −3.98                               *EYA2*
                    3                      rs9831671                   T      G    0.27    20 450          24.03                9.49E−07    0.43                   4.27                               *LMCD1*
  WM                16                     rs10514437                  G      A    0.03    −6617           31.97                1.56E−08    4.14                   −3.76                               *WWOX*
                    20                    rs117068934                  G      A    0.03    −5988           26.34                2.86E−07    1.01                   −3.41                             *SLC13A3*
                    6                      rs9361254                   G      T    0.13    −3106           24.10                9.16E−07    0.31                   −1.77             *MEI4*[a](#t1-fn2){ref-type="fn"}*, HTR1B*
                    18                    rs138549714                  G      GT   0.07    −3608           23.96                9.85E−07    0.29                   −2.05                              *MYOM1*
                    12                     rs11834561                  G      A    0.38    2071            23.92                1.00E−06    0.29                   1.18                               *USP44*
                    21                    rs200193477                  A      AT   0.26    3577            23.66                1.15E−06    0.27                   2.03                                *---*
  GM                4        rs114518130[b](#t1-fn3){ref-type="fn"}    G      A    0.01    14 973          39.04                4.15E−10    6.52                   6.13                               *IGFBP7*
                    7                      rs7786147                   C      T    0.11    −4135           28.10                1.15E−07    2.27                   −1.69                *MPLKIP*[c](#t1-fn4){ref-type="fn"}
                    3                     rs200355458                  C      CG   0.09    4657            27.74                1.39E−07    1.86                   1.91                                *OPA1*
                    8                      rs2565117                   C      A    0.01    −10 939         26.33                2.88E−07    1.12                   −4.48                              *ZMAT4*
                    18                    rs138087875                  A      AC   0.06    4789            25.78                3.83E−07    0.60                   1.96                               *CNDP1*
                    16                     rs12919005                  C      G    0.03    6973            25.55                4.31E−07    0.51                   2.85                                *TOX3*
                    9                      rs77196186                  C      T    0.05    −4970           24.77                6.45E−07    0.40                   −2.03                              *CAAP1*
                    16                     rs9889138                   G      A    0.07    4482            24.39                7.86E−07    0.34                   1.83                              *C16orf62*
                    14                     rs1092055                   T      C    0.45    2142            24.28                8.32E−07    0.34                   0.88                              *SLC35F4*
                    10                     rs11012877                  G      A    0.11    3683            24.23                8.54E−07    0.33                   1.51                               *CACNB2*
                    1                      rs2992041                   C      T    0.43    2516            24.05                9.37E−07    0.32                   1.03                                *CTH*
                    16                     rs7206373                   G      C    0.46    2084            23.77                1.09E−06    0.29                   0.85                              *SEC14L5*
  CSF               16                     rs7195044                   C      G    0.09    5619            26.55                2.56E−07    1.33                   9.54                               *RBFOX1*
                    17                     rs11867179                  C      G    0.24    3042            25.43                4.6E−07     0.53                   5.17                                *TBX4*
                    4                     rs113668862                  C      T    0.08    −4951           24.95                5.9E−07     0.43                   −8.41                               *FRG1*
                    18                     rs11875537                  T      G    0.44    2559            24.35                8.05E−07    0.37                   4.35                               *METTL4*

Abbreviations: CSF, cerebrospinal fluid; GM, gray matter; ICV, intracranial volume; LD, linkage disequalibrium; MAF, minor allele frequency; SNP, single-nucleotide polymorphism; WM, white matter.

Provisional or inferred status in RefSeq (next closest protein coding gene within 500 kb is also listed).

Genome-wide significant (*P*\<1.25 × 10^−8^), Bonferroni correction of 5 × 10^−8^ for four phenotypes.

Also known as c7orf11.

Note that all SNPs are imputed with the exception of rs10514437; see [Supplementary Figure 2](#sup1){ref-type="supplementary-material"} for a genotyping cluster plot of rs10514437. A1 is the effective allele and A2 is the reference allele. Diff./allele is the ratio of effect size over mean brain volume.

We define LD-independent SNPs as those with low LD (*r*^2^\<0.1) to a more significantly associated SNP within a 500 kb window.
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